I disse undersøgelser var procentdelen af patienter, der fik Tredaptive, nicotinsyre (depotformuleringer, poolede) eller placebo/ simvastatin (poolet), og som stoppede behandlingen på grund af flushing - relaterede symptomer (rødme, varme, kløe og prikken i huden) henholdsvis 7, 2%, 16, 6% og 0, 4%.
In these studies, the percentage of patients taking Tredaptive, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/ simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2%, 16.6%, and 0.4%, respectively.